55 results about "Pneumonia mrsa" patented technology

The invention provides a mycoplasma hyopneumoniae strain HN0613 which is isolated and identified to have better immunogenicity, and further provides a mycoplasma hyopneumoniae antigen prepared from the mycoplasma hyopneumoniae strain HN0613 and mycoplasma pneumonia pneumovax containing the mycoplasma hyopneumoniae antigen. The invention further provides a bivalent combined vaccine of porcine circovirus II and mycoplasma hyopneumoniae. The duplex combination vaccine comprises PCV (Porcine Circovirus) antigen II (inactivated porcine circovirus antigen II or PCV20 RF2 protein), inactivated mycoplasma hyopneumoniae and vaccine adjuvant. The combination vaccine can achieve the purpose of preventing the porcine circovirus disease and the mycoplasma pneumonia swine by injection once, and has a protective effect of preventing mycoplasma hyopneumoniae infection.

The invention discloses a pig mycoplasma pneumonia live attenuated vaccine and application thereof. A pig lung disease material infected by typical pig mycoplasma hyopneumoniae and not infected by other pathogens is screened and then is subcultured to the 100th generation through the lung of a baby rabbit, then pig mycoplasma hyopneumoniae strains are separated and are continuously subcultured through a culture medium; meanwhile, the mycoplasma hyopneumoniae AN306 is obtained through screening of a plurality of strains, and the preservation number of the mycoplasma hyopneumoniae AN306 is CCTCC M2012431. The invention also relates to a pig mycoplasma pneumonia live vaccine preparation based on the preparation of the attenuated vaccine strain. The pig mycoplasma pneumonia live vaccine preparation comprises a live attenuated vaccine strain, a pharmaceutically acceotable carrier or auxiliary ingredient and an adjuvant, and further comprises immunogens of other pathogens. The pig mycoplasma pneumonia live vaccine disclosed by the invention can be immunized in multiple ways and can enable animals to gain protection ability for resisting pig mycoplasma hyopneumoniae infection.

The invention relates to the technical field of biology, disclosing two pseudomonas aeruginosa virulent strains and a mink hemorrhagic pneumonia divalent inactivated vaccine prepared from the two strains. The pseudomonas aeruginosa virulent strains are inoculated in a culture medium to be amplified and cultured by ventilation; after the obtained cultured object is inactivated, the products are mixed at the ratio of 1-2:1; and adjuvant is added to prepare the mink hemorrhagic pneumonia divalent inactivated vaccine. The divalent inactivated vaccine disclosed by the invention has good immunity effect on mink hemorrhagic pneumonia, at least five-month protection periods can be obtained, the protection ratio is above 80%, the mink hemorrhagic pneumonia can be prevented, and the vaccine has good application prospect.

The invention discloses new klebsiella pneumoniae phage vB_KpnM_Bp5. The klebsiella pneumoniae phage (klebsiella pneumoniae phage) phage ) vB_KpnM_Bp5 is preserved in the China Center for Type CultureCollection (CCTCC) on June 13, 2019, and the preservation number is CCTCC NO:M 2019452. The phage has better disinfecting and sterilizing effects on host multidrug resistant klebsiella pneumoniae separated from piggery sewage, also has good disinfecting and sterilizing effects on other two multidrug resistant klebsiella pneumoniae separated from hospitals, is wide in antimicrobial spectrum, and can be applied to preparation of medicines for preventing and treating multidrug resistant klebsiella pneumoniae.

The invention discloses an anti-mycoplasma bovis monoclonal antibody, a hybridoma cell strain secreting the monoclonal antibody and an application. When the monoclonal antibody reacts with different mycoplasma strain mycoproteins, Western Blotting results indicate that the monoclonal antibody 3G11 only performs specific immune reaction with a mycoplasma bovis isolate, and does not react with mycoplasma mycoides SC (MmmSC), mycoplasma mycoides LC (MmmLC), mycoplasma capricolum pneumonia (Mccp), M.agalactiae, and M.ovipneumoniase. Therefore, the anti-mycoplasma bovis monoclonal antibody has good specificity, can be used for diagnosing and testing mycoplasma bovis infection, and provides an effective approach to prevent and control the disease.

Belonging to the molecular biology field, the invention relates to a primer set for respiratory tract infection pathogen detection, a rapid diagnostic kit and a detection method. The primer set can achieve one-time detection of the following 9 respiratory tract infection pathogens: influenza A virus, influenza B virus, respiratory syncytial virus, parainfluenza virus type I, parainfluenza virus type II and parainfluenza virus type III, adenovirus, mycoplasma pneumonia, legionella pneumonia, chlamydia pneumonia and human rhinovirus. The invention adopts solid phase recombinase-polymerase constant temperature gene amplification method to detect respiratory multiple infection pathogens. The primer set adopted by the invention for respiratory tract infection pathogen detection has strong specificity and high amplification efficiency, can effectively and rapidly detect the 9 pathogens simultaneously, and realizes multiplex detection.

The invention discloses a method for preparing an actinobacillus pleuropneumoniae (App) bacterial ghost and a method for preparing a subunit vaccine by loading a pasteurella antigen with the App bacterial ghost. A recombinant swine App bacterial ghost is prepared by controllable double-cracking technology and a pasteurella protection gene is introduced into an App bacterial ghost carrier, so that swine pleuropneumonia and a pasteurella bigeminal gene vaccine for preventing and treating swine pasteurellosis and swine pleuropneumonia are obtained. The preparation of the bacterial ghost carrier and the application of the bacterial ghost carrier to the prevention and treatment of important animal epidemic diseases are realized and a method is provided for the research of a multi-geminal gene vaccine at the same time. An animal experiment indicates that the protection rates of the bigeminal vaccine on infectious swine pleuropneumonia and pasteurellosis are up to 99 percent and 99.2 percent respectively.

The invention relates to preparation and application of a mycoplasma hyopneumoniae multi-epitope mucosal vaccine. A mycoplasma hyopneumoniae membrane protein, an adhesive protein P97, a lipoprotein P65, a specific membrane protein P46, a B cell epitope, a Th epitope, a CTL epitope and a cholera toxin subunit B are taken as a vaccine frame structure, a pRSETA carrier is cloned in through flexible linker connection, then Escherichia coli is transformed, and fermentation, purification and preparation technologies are carried out, so that the mycoplasma hyopneumoniae multi-epitope mucosal vaccine with ideal immunogenicity is obtained. A self-made mucosal adjuvant is used in a preparation process, so that production and using processes of the vaccine are simpler and more convenient. Animal experiments show that the mycoplasma hyopneumoniae multi-epitope mucosal vaccine not only has good safety but also can stimulate effective mucosal immunity, humoral immunity and cellular immune reactions.

The invention provides application of S. pneumoniae protein to resisting infection of S. pneumoniae. The endopeptidase O (PepO) of S. pneumoniae is a subcutaneous immunologic adjuvant, and the prepared S. pneumoniae protein vaccines have the good protection effects on resisting infection of S. pneumoniae through mixing and fusing expression of the subcutaneous immunologic adjuvant and 673rd to 863rd amino acid peptide fragment of zinc metal protease B (ZmpB).

Provided are a method and a kit for accurately and rapidly detecting ten types of targeting pneumonia bacteria: Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila, Klebsiella pneumoniae, Pseudomonas aeruginosa, Moraxella catarrhalis, methicillin-resistant Staphylococcus aureus (MRSA), and Staphylococcus aureus. A set of primer pairs directed to their respective target regions contained in the DnaJ gene, etc., of the ten types of pneumonia causative bacteria is designed for the ten bacterial strains and used to amplify gene products. A set of bacterial strain-specific probe pairs is further designed for the ten bacterial strains such that the probe pairs hybridize with the amplification products via sequences in the respective target regions differing from the sequences hybridized by the set of primer pairs. A first probe-bound labeled high molecular carrier in which plural types of first probes for the pneumonia bacteria are bound to a labeled high molecular carrier and a solid-phase second probe-carrying developing support are used as the set of probe pairs to perform nucleic acid chromatography.

The invention relates to a production method for pig mycoplasma pneumonia inactivated vaccine. The method takes an isolated mycoplasma hyopneumoniae (Mycoplasma hyopneumoniae Mhp) ZY strain with strong poison immunity and good epidemic focus as a production bacterial strain, and efficient culture medium, appropriate cultural method, inactivation technology and appropriate immunologic adjuvant areused to prepare the mycoplasma hyopneumoniae inactivated vaccine. The production method for the pig mycoplasma pneumonia inactivated vaccine has the advantages that the content CUU of inactivated antigens is no less than 1.5*108 per dose in the prepared vaccine, the use of the vaccine is safe, healthful 2-3-week-old piglets easy to be infected do not have local or whole-length untoward effect after inoculation and all live healthily; the vaccine comprises an effectiveness testing result with a matched group by using an assay of vaccination and challenge method, and the decrement rate of pneumonia of tested pigs in the matched group is no less than 75%; the vaccine is still safe and effective after being stored at 2-8 DEG C for 27 months; and the effectiveness testing of the vaccine also can be performed by using an IHA method to detect the titer of a rabbit serum mycoplasma hyopneumoniae antibody, which has great benefit for the effectiveness testing of the vaccine.

The invention discloses porcine mycoplasma pneumoniae and an application of the porcine mycoplasma pneumoniae. The porcine mycoplasma pneumoniae is mycoplasma bovis HNMhy1, has a collection number of CGMCC (China General Microbiological Culture Collection Center) NO: 13858 and is collected in China General Microbiological Culture Collection Center in Beijing, China on May 26, 2017. The porcine mycoplasma pneumoniae strain HNMhy1 is separated from a nursery pig having typical dyspnea and lung consolidation, has stable biological characteristics, and higher pathogenicity on the nursery pig, can cause a typical deep breathing symptom of the nursery pig and has good immunogenicity. A vaccine prepared from the porcine mycoplasma pneumoniae strain HNMhy1 is safe and reliable and has a better protection effect on the porcine primary atypical pneumonia.

The invention discloses an EGCG with an inhibitory effect on streptococcus pneumoniae pathogenicity and an application of EGCG with the inhibitory effect on the streptococcus pneumoniae pathogenicity for confirming that EGCG has no bacteriostatic activity for streptococcus pneumoniae, but can inhibit peptidase activity of SrtA to lower the pathogenicity of the streptococcus pneumoniae; the invention further provides a new pharmaceutical use of EGCG. Drug sensitivity tests, SrtA peptidase activity inhibition tests, Hep2 adherence inhibition tests and treatment tests of streptococcus pneumoniae infected mice confirm that EGCG plays a role of lowering the streptococcus pneumoniae pathogenicity.

The invention discloses a Chinese medicine preparation capable of curing pediatric asthmatic pneumonia. The asthmatic pneumonia belongs to the category of Chinese medicine 'pneumonia with dyspnea and cough', the pathogenesis includes that wheezing and coughing are probably caused by pathogen blocked in a lung, lung infection, heat transmission, phlegm production and reversed flow of phlegm along with air. Therefore, by means of the Chinese medicine preparation capable of curing the pediatric asthmatic pneumonia, the Chinese medicine of marsdenia tenacissima, callianthemus, small lilac, crepis phoenix, radix tetrastigme, vernonia cinerea, ardisa japonica blume, gynostemma pentaphyllum, cortex mori radicis, eriobotrya seguinii, ephedra, lanjiang lily bulb, aster, perny false fairybells rhizome, lotus seeds and gordon euryale seeds, and water are decocted into soup decoction to be drunk by a patient. By means of the clinical test of the hospital, the overall effective rate reaches 98.3%, the curing effect is stable, and the side effect is small.

Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromized patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.

The invention provides a serotype combination of a polyvalent pneumococci conjugate vaccine. Pneumococci serotypes 24 and 35 (24F and 35B) contained in the serotype combination of the polyvalent pneumococci conjugate vaccine are used for preventing the infection caused by the pneumococci which contains the serotypes.

The invention provides an inactivated vaccine prepared through a mink pseudomonas aeruginosa strain SD17. The inactivated vaccine comprises antigen and vaccine adjuvant, wherein the antigen is an inactivated pseudomonas aeruginosa strain SD17 and has the preservation number of CCTCC NO:M2016069. The prepared inactivated vaccine is safe and reliable, can provide effective homologous challenge protection and can produce strong immunity after immunity, the morbidity and death rate of vaccinated mink groups are both remarkably decreased, the prevalence and transmission of mink hemorrhagic pneumonia can be effectively prevented, the economic loss caused by the disease to the fur-bearing animal breeding industry is reduced, and wide application prospects are achieved.

The invention discloses a Streptococcus pneumoniae protein vaccine, which is a Streptococcus pneumoniae capsule saccharide-protein conjugate obtained by covalently linking one or a variety of Streptococcus pneumoniae capsule saccharides and a carrier protein, wherein the carrier protein is lectin. Compared to the Streptococcus pneumoniae protein vaccine in the prior art, the Streptococcus pneumoniae protein vaccine of the present invention has the following advantages that the administration mode of the Streptococcus pneumoniae protein vaccine is intranasal administration, wherein the intranasal administration is convenient and rapid compared to intramuscular injection; the Streptococcus pneumoniae protein vaccine can be used as the commercially available Streptococcus pneumoniae supplementary immunization vaccine; and when the large-scale epidemic situation occurs, the Streptococcus pneumoniae protein vaccine can be temporarily used as the emergency vaccine, and can provide the immunization foundation for the subsequent vaccination of the commercially available Streptococcus pneumoniae vaccine.

The invention provides an inactivated mink Pseudomonas aeruginosa vaccine, which includes an antigen and a vaccine adjuvant, wherein the antigen used is type B mink Pseudomonas aeruginosa LN03 strain, and the preservation number is CCTCC NO: M2016068. The inactivated vaccine prepared by the invention is safe and reliable, can provide effective homologous virus attack protection, can produce strong immunity after immunization, significantly reduces the morbidity and mortality of inoculated mink groups, and can effectively prevent the prevalence of mink hemorrhagic pneumonia It can reduce the economic loss caused by the disease to the fur animal breeding industry, and has broad application prospects.

The invention provides a bivalent inactivated vaccine to bacterium pyocyaneum for mink. The vaccine comprises an antigen and a vaccine adjuvant, wherein the antigen is inactivated mink bacterium pyocyaneum LN03 strain having a preservation number of CCTCC NO:M2016068 and inactivated pyocyaneum SD17 having a preservation number of CCTCC NO:M2016069. The inactivated vaccine is safe and reliable and can provide effective homologous attacking protection, strong immunity can be generated after immunization, the incidence and death rate of a vaccinated mink group can be remarkably reduced, prevalence and transmission of hemorrhagic pneumonia of mink can be effectively prevented, and economic loss of hemorrhagic pneumonia of mink for fur-bearing animal breeding can be reduced. The bivalent inactivated vaccine to bacterium pyocyaneum for mink has a wide application prospect.